UT MD Anderson Cancer Center
Welcome,         Profile    Billing    Logout  
 1155 Trials 
1643 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, John C
NCT03412396: Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Active, not recruiting
2
50
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Quality-of-Life Assessment, Quality of Life Assessment, Radical Prostatectomy, Prostatovesiculectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
03/26
03/26
NCT03773471: A Multi-Center Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making

Completed
N/A
69
US
Mobile Health App
Mayo Clinic
Rheumatoid Arthritis
06/23
06/23
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
03/25
03/25
Wells, Robert
HDClarity, NCT02855476: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Recruiting
N/A
2500
Europe, Canada, US, RoW
University College, London, CHDI Foundation, Inc.
Huntington's Disease
04/25
04/27
Karp, Daniel D
NCT02266745 / 2021-001308-14: A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Active, not recruiting
2
109
Europe, US
PT-112 Injection, PT-112
Promontory Therapeutics Inc., Promontory Therapeutics Inc.
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
08/24
04/25
PAVE-1, NCT03409458: A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Checkmark From PAVE-1 trial in combination with PT-112 in advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From PAVE-1 trial in combination with PT-112 in advanced solid tumors at ESMO 2020
Completed
1/2
68
Europe, US
PT-112, avelumab
Promontory Therapeutics Inc., Pfizer, EMD Serono
Non-Small Cell Lung Cancer (NSCLC)
06/22
08/22
NCT02192385: PT-112 in Advanced Solid Tumors

Recruiting
1
84
US
PT-112, Phone Call
M.D. Anderson Cancer Center, Phosplatin Therapeutics
Solid Tumors
07/20
 
Ajani, Jaffer A
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting
1/2
129
US
MRG002
Shanghai Miracogen Inc.
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
10/22
12/24
NCT03943004: Trial of DFP-14927 in Advanced Solid Tumors

Recruiting
1
30
US
DFP-14927
Delta-Fly Pharma, Inc.
Solid Tumor, Cancer
03/26
06/26
NCT03395847: Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Completed
1
9
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma
01/23
01/23
NCT04522336: Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Active, not recruiting
1
16
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Localized Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma
07/25
07/25
NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed
1
17
US
LM-302
Turning Point Therapeutics, Inc.
Advanced Solid Tumor
01/24
01/24
O'Brien, Susan M
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
ELM-1, NCT02290951: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Jan 2023 - Dec 2023: Approval for blood cancer
Jul 2023 - Dec 2023: Submission in US for r/r/ follicular lymphoma
Checkmark Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Dec 2022 - Dec 2022: Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Checkmark FDA lifts partial clinical hold on study of odronextamab
More
Active, not recruiting
1
200
Europe, US, RoW
Odronextamab multiple dose levels, REGN1979
Regeneron Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
09/25
09/25
Skibber, John M
NCI-2020-07464, NCT00648635: Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations

Active, not recruiting
N/A
116
US
Questionnaire, Survey
M.D. Anderson Cancer Center
Rectal Cancer
09/27
09/27
Cox, James D
ROADMAP, NCT06771050: Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform () Trial

Not yet recruiting
4
2500
RoW
Debridement and Implant Retention (DAIR), Revision Arthroplasty - Single stage revision, Antibiotic Choice, No intervention: Standard of Care "Backbone antibiotics", Intervention: Standard of care " Backbone antibiotics" + Rifampicin antibiotics, Antibiotic duration Part A - Single stage revision, shorter duration - 6 weeks, longer duration - 12 weeks, Antibiotic Duration Part B - Two stage revision, Extended antibiotic prophylaxis following 2nd stage Revision operation, No extended antibiotic prophylaxis following 2nd stage Revision operation
University of Newcastle, Australia, Hunter Medical Research Institute (HMRI), The University of Western Australia, Michael Garron Hospital, Aotearoa Clinical Trials, Exeter Orthopaedic Trial unit, University of Sydney, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
02/28
12/29
Gilbert, Mark R
hSTAR GBM, NCT05052957: (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting
2
16
US
P140K-MGMT, O6-benzylguanine, BG, Photon Based Radiotherapy, temozolomide, TMZ, Filgrastim, G-CSF,Granulocyte-Colony Stimulating Factor, carmustine, BCNU,bis-chloronitrosourea
Leland Metheny, National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
06/26
12/26
NCT04817254: Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruiting
2
47
US
TMZ, ipilimumab 3mg/kg, Nivolumab, ipilimumab 1mg/kg
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Malignant Glioma
11/25
12/26
ONC206-001, NCT04541082: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Recruiting
1
102
US
ONC206
Chimerix, National Institutes of Health (NIH)
Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor
12/25
12/26
Champlin, Richard E
NCT02400255: Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Completed
2
30
US
Crenolanib besylate, CP-868,596-26
Arog Pharmaceuticals, Inc.
Acute Myeloid Leukemia
05/22
05/22
NCT03622788: Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

Recruiting
1/2
24
US
Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATS, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytokine-treated Veto Cells, Activated Veto Cells, Activated Veto T-cells, Veto CD8-positive T-cells, Veto Cell, Veto Cells, Veto-enhanced CTL, Veto-enhanced Cytotoxic T-cell, Fludarabine, Fluradosa, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
12/25
12/25
Giralt, Sergio
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/25
10/25
NCT01745588: Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
23
US
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Memorial Sloan Kettering Cancer Center, Celgene Corporation, Weill Medical College of Cornell University, North Shore University Hospital, Rutgers Cancer Institute of New Jersey, State University of New York - Upstate Medical University
Multiple Myeloma
12/25
12/25
NCT01758328: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed
1
29
US
busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
03/25
03/25
NCT03276481: Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Completed
N/A
47
US
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
07/23
07/23
NCT02677064: Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Recruiting
N/A
1365
US
assessments
Memorial Sloan Kettering Cancer Center
Acute Leukemia, Newly Diagnosed, Relapsed
02/26
02/26
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation

Recruiting
N/A
91
US
Home monitoring teleconsult visits, Patient Reported Outcomes (PRO), Caregiver Reported Outcomes instruments
Memorial Sloan Kettering Cancer Center
Plasma Cell Dyscrasia
01/27
01/27
NCT05737732: The Ambient Light Multiple Myeloma Study

Recruiting
N/A
200
US
Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
Icahn School of Medicine at Mount Sinai
Multiple Myeloma
06/27
06/27
Khouri, Issa
NCT01919619: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Completed
2
41
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
05/24
05/24
NCT03856216: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Recruiting
2
44
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Bendamustine, SDX-105, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
03/27
03/27
NCI-2012-02072, NCT01664910: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed
1/2
27
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
06/23
06/23
NCT04022239: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
1/2
25
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Bendamustine, SDX-105, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm
07/25
07/25
Pagliaro, Lance
InPACT, NCT02305654 / 2015-001199-23: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Recruiting
3
200
Europe, US
ILND - Inguinal Lymph Node Dissection, Paclitaxel, Taxol, Ifosfamide, Mitoxana, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection
Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Penis, Usual Type
05/27
11/27
NCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
2/3
249
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Therapeutic Conventional Surgery, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
09/27
09/27
NCT03866382: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
2
314
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
02/26
02/26
NCT06104618: Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Recruiting
2
28
US
Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG-22CE, Enfortumab Vedotin-ejfv, Padcev, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Axial Tomorgraphy, computed axial tomogrpahy, Computerized Tomography, computerized tmography, Computerized Tomography (CT) scan, CT, CT Scan, Magnetic Resonance Imaging, MRI, Magnetic Resonance Imaging (MRI), Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Nuclear Resonance Magnetic Imaging, structural MRI, sMRI
Mayo Clinic
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma
11/26
11/26
Kantarjian, Hagop M
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
120
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox
M.D. Anderson Cancer Center, TEVA, Leukemia SPORE
Leukemia
07/26
07/26
NCT02689440: Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Active, not recruiting
2
155
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Laboratory Biomarker Analysis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
12/40
12/40
Rosenthal, David I
NCT06167291: Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)

Recruiting
2
240
US
Arm 1- Ipsilateral
M.D. Anderson Cancer Center
Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
12/27
12/27
VOCAL, NCT03759431: Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer

Active, not recruiting
2
155
Canada, US
Vocal-cord Radiotherapy, Complete Larynx Radiotherapy
Centre hospitalier de l'Université de Montréal (CHUM), London Health Sciences Centre, M.D. Anderson Cancer Center
Cancer Neck, Larynx Cancer, Glottis Tumor
12/26
12/26
Wolf, Judith K
NCT05336097: Pathways to Empowerment for Persons Living in Persistent Poverty

Completed
N/A
35
Europe
Pathways to Empowerment, Krachtwerk
Radboud University Medical Center, Movisie, Municipality of Meppel, the Netherlands, Municipality of Midden-Groningen, the Netherlands, Municipality of Nieuwegein, the Netherlands, Municipality of Nijmegen, the Netherlands, Municipality of Oss, the Netherlands, Stichting Lezen en Schrijven, Vereniging Valente, Voedselbanken Nederland, Wageningen University and Research
Perceived Stress, Persistent Poverty
07/23
07/23
Pettaway, Curtis A
InPACT, NCT02305654 / 2015-001199-23: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Recruiting
3
200
Europe, US
ILND - Inguinal Lymph Node Dissection, Paclitaxel, Taxol, Ifosfamide, Mitoxana, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection
Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Penis, Usual Type
05/27
11/27
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
11/26
11/27
NCT04996849: Contemporary Characteristics of Penile Cancer

Recruiting
N/A
1000
US
Data Capture, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Penile Carcinoma, Squamous Cell Carcinoma of the Penis
12/26
12/26
NCT05842031: Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

Recruiting
N/A
20
US
Quality of Life Questionnaires, Patient Educational Needs, Symptom Management
M.D. Anderson Cancer Center
Penile Cancer
12/26
12/26
Bruera, Eduardo
NCT04196972: Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

Active, not recruiting
N/A
36
US
Communication Intervention, Questionnaire Administration, Waiting List, Waitlist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
12/26
12/26
NCT04119037: Cordotomy in Reducing Pain in Patients With Advanced Cancer

Active, not recruiting
N/A
27
US
Cordotomy, Morphine, Questionnaire Administration, Sham Intervention
M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institute of Nursing Research (NINR)
Advanced Malignant Neoplasm
09/25
12/25
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/25
06/26
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
100
US
Single Agent Asciminib, ABL001, Low TKI, Elective Free Treatment
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/32
02/32
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT05905328: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Recruiting
1/2
54
US
CTO1681 10 μg, CTO1681 20 μg, CTO1681 30 μg
CytoAgents, Inc., TFS HealthScience
Cytokine Release Syndrome
06/27
06/27
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Terminated
1
80
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
05/21
05/21
P-TRP-2447-14, NCT02530034: Hu8F4 in Treating Patients with Advanced Hematologic Malignancies

Active, not recruiting
1
72
US
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
01/26
01/26
Lang, Frederick F
NCT03896568: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recruiting
1
36
US
Oncolytic Adenovirus Ad5-DNX-2401, Ad5-Delta24RGD, DNX-2401, DNX2401, Oncolytic Ad5-Delta 24RGD, Oncolytic Adenovirus Ad5-Delta 24RGD, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, DNAtrix, Inc.
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
09/27
09/27
Lu, Charles
NCT06745882: Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Recruiting
2
318
US
Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC, Foundation Medicine, Go-2 Lung
Non-small Cell Lung Cancer
01/30
01/30
Papadimitrakopoulou, Vassiliki
AURA3, NCT02151981 / 2014-000594-39: AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark Regulatory decision for lung cancer
Jul 2017 - Jan 2018: Regulatory decision for lung cancer
Checkmark Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
Jul 2017 - Apr 2017: Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
Checkmark Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
More
Completed
3
421
Europe, Canada, Japan, US, RoW
Chemotherapy, Osimertinib, Platinum-based Doublet-Chemotherapy, Cross-over to Osimertinib
AstraZeneca
Anticancer Treatment
04/16
12/23
Lung-Map Sub-Study, NCT02785952: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Active, not recruiting
3
275
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
12/19
04/25
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting
2/3
10000
US
Screening Platform
SWOG Cancer Research Network, National Cancer Institute (NCI)
Previously Treated Non-Small Cell Lung Cancer
01/29
01/29
Coleman, Robert E
GOG-0213, NCT00565851: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SGO 2015
Mar 2015 - Mar 2015: SGO 2015
Active, not recruiting
3
1052
Japan, US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
04/19
01/28
Strom, Eric A
NCT00929214: Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Active, not recruiting
2
35
US
Standard Therapy, Chemotherapy, Endocrine Therapy, Systemic Chemotherapy, Local Therapy, Radiation Therapy, RT, XRT, Surgery
M.D. Anderson Cancer Center
Breast Cancer
12/25
12/25
NCT01245712: Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Active, not recruiting
2
200
US
Accelerated Partial Breast Irradiation, APBI, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
12/32
12/32
Puduvalli, Vinay K
NCT02337686: Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma
05/17
12/26
NCT05879120: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Withdrawn
2
10
US
Pembrolizumab, Keytruda, MK-3475, SCH-900475, Exablate MRgFUS + neoadjuvant pembolizumab
M.D. Anderson Cancer Center, InSightec, Merck Sharp & Dohme LLC
Recurrent Glioblastoma
10/24
10/24
NCT00555399: Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Terminated
1/2
55
US
Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Isotretinoin, cRA, Accutane, 13-cis-Retinoic Acid, Surgical Resection, Temozolomide, Temodar
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Anaplastic Glioma
01/20
01/20
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT00102648: Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Active, not recruiting
1
34
US
Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
03/25
12/25
NCT01430351: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Active, not recruiting
1
144
US
Mefloquine, Memantine Hydrochloride, Ebixia, Namenda, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
09/25
09/25
Glisson, Bonnie S
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
Siefker-Radtke, Arlene
NCT00082706: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Active, not recruiting
2
46
US
5-Fluorouracil (5-FU), 5-FU, Adrucil, Efudex, Leucovorin, Citrovorum, Wellcovorin, Cisplatin, Platinol-AQ, Platinol, CDDP, Gemcitabine, Gemcitabine Hydrochloride, Gemzar
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Bladder Cancer, Urethral Cancer, Urachal Cancer
12/25
12/25
NCT02420847: Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1/2
57
US
Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
12/25
12/25
NCT00479128: Bortezomib with Gemcitabine/Doxorubicin in Patients with Urothelial Cancer and Other Solid Tumors

Active, not recruiting
1
80
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Doxorubicin, Adriamycin, AD, Hydroxydaunomycin hydrochloride
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Solid Tumor, Urethral Cancer
09/26
09/26
Wen, Patrick Y
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04406272: VB-111 in Surgically Accessible Recurrent/Progressive GBM

Terminated
2
15
US
VB11, Ofranergene obadenovec, Surgery, Placebo, Bevacizumab, Avastin
Dana-Farber Cancer Institute, Vascular Biogenics Ltd. operating as VBL Therapeutics
Glioblastoma, Recurrent Glioblastoma
08/24
08/24
NCT05463848: Surgical Pembro +/- Olaparib W TMZ for RGBM

Recruiting
2
78
US
Pembrolizumab, MK3475, Olaparib, MK-7339, Temozolomide, Temodar
L. Nicolas Gonzalez Castro, MD, PhD, Merck Sharp & Dohme LLC
Glioblastoma, Recurrent Glioblastoma
08/25
04/26
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
460
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
02/27
04/27
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT00268385: Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Active, not recruiting
1
83
US
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
10/18
04/25
NCT02852655: A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Active, not recruiting
1
60
US
MK-3475, Pembrolizumab
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Brain Cancer
06/22
01/26
GMCI, NCT03576612: , Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas

Completed
1
41
US
AdV-tk, Aglatimagene Besadenovec, Valacyclovir, 124832-26-4, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine, Zelitrex, Radiation, Irradiate, irradiation, radiotherapy, RT, Temozolomide, TMZ, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Laboratory Biomarker Analysis
Candel Therapeutics, Inc., National Cancer Institute (NCI), Bristol-Myers Squibb
Glioma, Malignant
06/23
06/23
NCT04606316: Surgical Nivolumab And Ipilimumab For Recurrent GBM

Active, not recruiting
1
63
US
Nivolumab-Placebo, Nivolumab, Opdivo, Ipilimumab-Placebo, Ipilimumab, Yervoy, Surgery, Resection
Patrick Wen, MD, Bristol-Myers Squibb
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
06/25
12/25
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
180
Europe, Japan, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
09/26
09/26
NCT04656535: AB154 Combined With AB122 for Recurrent Glioblastoma

Active, not recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
06/25
12/25
Neelapu, Sattva S
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Active, not recruiting
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
GLEAN-1, NCT04735471: A Phase 1 Study of ADI-001 in B Cell Malignancies

Active, not recruiting
1
78
US
ADI-001, Fludarabine, Cyclophosphamide
Adicet Therapeutics
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
07/25
12/27
NCT05773040: A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Recruiting
1
33
US
JV-213, Leukapheresis
M.D. Anderson Cancer Center
Lymphomas, B-cell Lymphomas
12/25
12/27
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Active, not recruiting
1
16
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
11/25
11/38
Tu, Shi-Ming
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
A031701, NCT03609216: Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Recruiting
2
271
US
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
02/27
02/29
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
NCT06044025: A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

Recruiting
1
30
US
Metformin, Turmeric
University of Arkansas
Castration Sensitive Prostate Cancer
10/26
10/27
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davis, John C
NCT03412396: Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Active, not recruiting
2
50
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Quality-of-Life Assessment, Quality of Life Assessment, Radical Prostatectomy, Prostatovesiculectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
03/26
03/26
NCT03773471: A Multi-Center Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making

Completed
N/A
69
US
Mobile Health App
Mayo Clinic
Rheumatoid Arthritis
06/23
06/23
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
03/25
03/25
Wells, Robert
HDClarity, NCT02855476: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Recruiting
N/A
2500
Europe, Canada, US, RoW
University College, London, CHDI Foundation, Inc.
Huntington's Disease
04/25
04/27
Karp, Daniel D
NCT02266745 / 2021-001308-14: A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Active, not recruiting
2
109
Europe, US
PT-112 Injection, PT-112
Promontory Therapeutics Inc., Promontory Therapeutics Inc.
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
08/24
04/25
PAVE-1, NCT03409458: A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Checkmark From PAVE-1 trial in combination with PT-112 in advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: From PAVE-1 trial in combination with PT-112 in advanced solid tumors at ESMO 2020
Completed
1/2
68
Europe, US
PT-112, avelumab
Promontory Therapeutics Inc., Pfizer, EMD Serono
Non-Small Cell Lung Cancer (NSCLC)
06/22
08/22
NCT02192385: PT-112 in Advanced Solid Tumors

Recruiting
1
84
US
PT-112, Phone Call
M.D. Anderson Cancer Center, Phosplatin Therapeutics
Solid Tumors
07/20
 
Ajani, Jaffer A
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting
1/2
129
US
MRG002
Shanghai Miracogen Inc.
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
10/22
12/24
NCT03943004: Trial of DFP-14927 in Advanced Solid Tumors

Recruiting
1
30
US
DFP-14927
Delta-Fly Pharma, Inc.
Solid Tumor, Cancer
03/26
06/26
NCT03395847: Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Completed
1
9
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma
01/23
01/23
NCT04522336: Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Active, not recruiting
1
16
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Localized Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma
07/25
07/25
NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed
1
17
US
LM-302
Turning Point Therapeutics, Inc.
Advanced Solid Tumor
01/24
01/24
O'Brien, Susan M
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
ELM-1, NCT02290951: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Jan 2023 - Dec 2023: Approval for blood cancer
Jul 2023 - Dec 2023: Submission in US for r/r/ follicular lymphoma
Checkmark Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Dec 2022 - Dec 2022: Presentation of ELM-1 and ELM-2 data from trial for DLBCL at ASH 2022
Checkmark FDA lifts partial clinical hold on study of odronextamab
More
Active, not recruiting
1
200
Europe, US, RoW
Odronextamab multiple dose levels, REGN1979
Regeneron Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
09/25
09/25
Skibber, John M
NCI-2020-07464, NCT00648635: Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations

Active, not recruiting
N/A
116
US
Questionnaire, Survey
M.D. Anderson Cancer Center
Rectal Cancer
09/27
09/27
Cox, James D
ROADMAP, NCT06771050: Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform () Trial

Not yet recruiting
4
2500
RoW
Debridement and Implant Retention (DAIR), Revision Arthroplasty - Single stage revision, Antibiotic Choice, No intervention: Standard of Care "Backbone antibiotics", Intervention: Standard of care " Backbone antibiotics" + Rifampicin antibiotics, Antibiotic duration Part A - Single stage revision, shorter duration - 6 weeks, longer duration - 12 weeks, Antibiotic Duration Part B - Two stage revision, Extended antibiotic prophylaxis following 2nd stage Revision operation, No extended antibiotic prophylaxis following 2nd stage Revision operation
University of Newcastle, Australia, Hunter Medical Research Institute (HMRI), The University of Western Australia, Michael Garron Hospital, Aotearoa Clinical Trials, Exeter Orthopaedic Trial unit, University of Sydney, University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections
02/28
12/29
Gilbert, Mark R
hSTAR GBM, NCT05052957: (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting
2
16
US
P140K-MGMT, O6-benzylguanine, BG, Photon Based Radiotherapy, temozolomide, TMZ, Filgrastim, G-CSF,Granulocyte-Colony Stimulating Factor, carmustine, BCNU,bis-chloronitrosourea
Leland Metheny, National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
06/26
12/26
NCT04817254: Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruiting
2
47
US
TMZ, ipilimumab 3mg/kg, Nivolumab, ipilimumab 1mg/kg
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Malignant Glioma
11/25
12/26
ONC206-001, NCT04541082: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Recruiting
1
102
US
ONC206
Chimerix, National Institutes of Health (NIH)
Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor
12/25
12/26
Champlin, Richard E
NCT02400255: Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Completed
2
30
US
Crenolanib besylate, CP-868,596-26
Arog Pharmaceuticals, Inc.
Acute Myeloid Leukemia
05/22
05/22
NCT03622788: Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

Recruiting
1/2
24
US
Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATS, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytokine-treated Veto Cells, Activated Veto Cells, Activated Veto T-cells, Veto CD8-positive T-cells, Veto Cell, Veto Cells, Veto-enhanced CTL, Veto-enhanced Cytotoxic T-cell, Fludarabine, Fluradosa, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
12/25
12/25
Giralt, Sergio
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Active, not recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
01/25
04/25
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/25
10/25
NCT01745588: Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
2
23
US
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Memorial Sloan Kettering Cancer Center, Celgene Corporation, Weill Medical College of Cornell University, North Shore University Hospital, Rutgers Cancer Institute of New Jersey, State University of New York - Upstate Medical University
Multiple Myeloma
12/25
12/25
NCT01758328: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed
1
29
US
busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
03/25
03/25
NCT03276481: Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Completed
N/A
47
US
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
07/23
07/23
NCT02677064: Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Recruiting
N/A
1365
US
assessments
Memorial Sloan Kettering Cancer Center
Acute Leukemia, Newly Diagnosed, Relapsed
02/26
02/26
NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation

Recruiting
N/A
91
US
Home monitoring teleconsult visits, Patient Reported Outcomes (PRO), Caregiver Reported Outcomes instruments
Memorial Sloan Kettering Cancer Center
Plasma Cell Dyscrasia
01/27
01/27
NCT05737732: The Ambient Light Multiple Myeloma Study

Recruiting
N/A
200
US
Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
Icahn School of Medicine at Mount Sinai
Multiple Myeloma
06/27
06/27
Khouri, Issa
NCT01919619: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Completed
2
41
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
05/24
05/24
NCT03856216: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Recruiting
2
44
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Bendamustine, SDX-105, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
03/27
03/27
NCI-2012-02072, NCT01664910: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed
1/2
27
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
06/23
06/23
NCT04022239: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
1/2
25
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Bendamustine, SDX-105, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim-sndz, Filgrastim Biosimilar Filgrastim-sndz, Zarxio, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, CellCept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid System Neoplasm
07/25
07/25
Pagliaro, Lance
InPACT, NCT02305654 / 2015-001199-23: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Recruiting
3
200
Europe, US
ILND - Inguinal Lymph Node Dissection, Paclitaxel, Taxol, Ifosfamide, Mitoxana, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection
Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Penis, Usual Type
05/27
11/27
NCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
2/3
249
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Therapeutic Conventional Surgery, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
09/27
09/27
NCT03866382: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
2
314
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
02/26
02/26
NCT06104618: Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Recruiting
2
28
US
Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG-22CE, Enfortumab Vedotin-ejfv, Padcev, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Axial Tomorgraphy, computed axial tomogrpahy, Computerized Tomography, computerized tmography, Computerized Tomography (CT) scan, CT, CT Scan, Magnetic Resonance Imaging, MRI, Magnetic Resonance Imaging (MRI), Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Nuclear Resonance Magnetic Imaging, structural MRI, sMRI
Mayo Clinic
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma
11/26
11/26
Kantarjian, Hagop M
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
120
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox
M.D. Anderson Cancer Center, TEVA, Leukemia SPORE
Leukemia
07/26
07/26
NCT02689440: Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Active, not recruiting
2
155
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Laboratory Biomarker Analysis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
12/40
12/40
Rosenthal, David I
NCT06167291: Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)

Recruiting
2
240
US
Arm 1- Ipsilateral
M.D. Anderson Cancer Center
Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
12/27
12/27
VOCAL, NCT03759431: Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer

Active, not recruiting
2
155
Canada, US
Vocal-cord Radiotherapy, Complete Larynx Radiotherapy
Centre hospitalier de l'Université de Montréal (CHUM), London Health Sciences Centre, M.D. Anderson Cancer Center
Cancer Neck, Larynx Cancer, Glottis Tumor
12/26
12/26
Wolf, Judith K
NCT05336097: Pathways to Empowerment for Persons Living in Persistent Poverty

Completed
N/A
35
Europe
Pathways to Empowerment, Krachtwerk
Radboud University Medical Center, Movisie, Municipality of Meppel, the Netherlands, Municipality of Midden-Groningen, the Netherlands, Municipality of Nieuwegein, the Netherlands, Municipality of Nijmegen, the Netherlands, Municipality of Oss, the Netherlands, Stichting Lezen en Schrijven, Vereniging Valente, Voedselbanken Nederland, Wageningen University and Research
Perceived Stress, Persistent Poverty
07/23
07/23
Pettaway, Curtis A
InPACT, NCT02305654 / 2015-001199-23: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Recruiting
3
200
Europe, US
ILND - Inguinal Lymph Node Dissection, Paclitaxel, Taxol, Ifosfamide, Mitoxana, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection
Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Penis, Usual Type
05/27
11/27
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
11/26
11/27
NCT04996849: Contemporary Characteristics of Penile Cancer

Recruiting
N/A
1000
US
Data Capture, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Penile Carcinoma, Squamous Cell Carcinoma of the Penis
12/26
12/26
NCT05842031: Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

Recruiting
N/A
20
US
Quality of Life Questionnaires, Patient Educational Needs, Symptom Management
M.D. Anderson Cancer Center
Penile Cancer
12/26
12/26
Bruera, Eduardo
NCT04196972: Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

Active, not recruiting
N/A
36
US
Communication Intervention, Questionnaire Administration, Waiting List, Waitlist
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
12/26
12/26
NCT04119037: Cordotomy in Reducing Pain in Patients With Advanced Cancer

Active, not recruiting
N/A
27
US
Cordotomy, Morphine, Questionnaire Administration, Sham Intervention
M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institute of Nursing Research (NINR)
Advanced Malignant Neoplasm
09/25
12/25
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/25
06/26
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
100
US
Single Agent Asciminib, ABL001, Low TKI, Elective Free Treatment
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/32
02/32
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT05905328: Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Recruiting
1/2
54
US
CTO1681 10 μg, CTO1681 20 μg, CTO1681 30 μg
CytoAgents, Inc., TFS HealthScience
Cytokine Release Syndrome
06/27
06/27
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Terminated
1
80
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
05/21
05/21
P-TRP-2447-14, NCT02530034: Hu8F4 in Treating Patients with Advanced Hematologic Malignancies

Active, not recruiting
1
72
US
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
01/26
01/26
Lang, Frederick F
NCT03896568: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recruiting
1
36
US
Oncolytic Adenovirus Ad5-DNX-2401, Ad5-Delta24RGD, DNX-2401, DNX2401, Oncolytic Ad5-Delta 24RGD, Oncolytic Adenovirus Ad5-Delta 24RGD, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, DNAtrix, Inc.
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
09/27
09/27
Lu, Charles
NCT06745882: Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Recruiting
2
318
US
Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC, Foundation Medicine, Go-2 Lung
Non-small Cell Lung Cancer
01/30
01/30
Papadimitrakopoulou, Vassiliki
AURA3, NCT02151981 / 2014-000594-39: AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark Regulatory decision for lung cancer
Jul 2017 - Jan 2018: Regulatory decision for lung cancer
Checkmark Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
Jul 2017 - Apr 2017: Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
Checkmark Regulatory decision (based on AURA3 trial) for ≥2nd-line advanced EGFRm T790M NSCLC
More
Completed
3
421
Europe, Canada, Japan, US, RoW
Chemotherapy, Osimertinib, Platinum-based Doublet-Chemotherapy, Cross-over to Osimertinib
AstraZeneca
Anticancer Treatment
04/16
12/23
Lung-Map Sub-Study, NCT02785952: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Active, not recruiting
3
275
Canada, US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
12/19
04/25
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting
2/3
10000
US
Screening Platform
SWOG Cancer Research Network, National Cancer Institute (NCI)
Previously Treated Non-Small Cell Lung Cancer
01/29
01/29
Coleman, Robert E
GOG-0213, NCT00565851: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SGO 2015
Mar 2015 - Mar 2015: SGO 2015
Active, not recruiting
3
1052
Japan, US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
04/19
01/28
Strom, Eric A
NCT00929214: Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Active, not recruiting
2
35
US
Standard Therapy, Chemotherapy, Endocrine Therapy, Systemic Chemotherapy, Local Therapy, Radiation Therapy, RT, XRT, Surgery
M.D. Anderson Cancer Center
Breast Cancer
12/25
12/25
NCT01245712: Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Active, not recruiting
2
200
US
Accelerated Partial Breast Irradiation, APBI, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
12/32
12/32
Puduvalli, Vinay K
NCT02337686: Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma
05/17
12/26
NCT05879120: Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Withdrawn
2
10
US
Pembrolizumab, Keytruda, MK-3475, SCH-900475, Exablate MRgFUS + neoadjuvant pembolizumab
M.D. Anderson Cancer Center, InSightec, Merck Sharp & Dohme LLC
Recurrent Glioblastoma
10/24
10/24
NCT00555399: Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Terminated
1/2
55
US
Vorinostat, SAHA, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Isotretinoin, cRA, Accutane, 13-cis-Retinoic Acid, Surgical Resection, Temozolomide, Temodar
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC
Glioblastoma Multiforme, Anaplastic Glioma
01/20
01/20
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT00102648: Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Active, not recruiting
1
34
US
Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
03/25
12/25
NCT01430351: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Active, not recruiting
1
144
US
Mefloquine, Memantine Hydrochloride, Ebixia, Namenda, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
09/25
09/25
Glisson, Bonnie S
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
Siefker-Radtke, Arlene
NCT00082706: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Active, not recruiting
2
46
US
5-Fluorouracil (5-FU), 5-FU, Adrucil, Efudex, Leucovorin, Citrovorum, Wellcovorin, Cisplatin, Platinol-AQ, Platinol, CDDP, Gemcitabine, Gemcitabine Hydrochloride, Gemzar
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Bladder Cancer, Urethral Cancer, Urachal Cancer
12/25
12/25
NCT02420847: Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1/2
57
US
Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
12/25
12/25
NCT00479128: Bortezomib with Gemcitabine/Doxorubicin in Patients with Urothelial Cancer and Other Solid Tumors

Active, not recruiting
1
80
US
Bortezomib, Velcade, LDP-341, MLN341, PS-341, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Doxorubicin, Adriamycin, AD, Hydroxydaunomycin hydrochloride
M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.
Solid Tumor, Urethral Cancer
09/26
09/26
Wen, Patrick Y
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04406272: VB-111 in Surgically Accessible Recurrent/Progressive GBM

Terminated
2
15
US
VB11, Ofranergene obadenovec, Surgery, Placebo, Bevacizumab, Avastin
Dana-Farber Cancer Institute, Vascular Biogenics Ltd. operating as VBL Therapeutics
Glioblastoma, Recurrent Glioblastoma
08/24
08/24
NCT05463848: Surgical Pembro +/- Olaparib W TMZ for RGBM

Recruiting
2
78
US
Pembrolizumab, MK3475, Olaparib, MK-7339, Temozolomide, Temodar
L. Nicolas Gonzalez Castro, MD, PhD, Merck Sharp & Dohme LLC
Glioblastoma, Recurrent Glioblastoma
08/25
04/26
INSIGhT, NCT02977780: INdividualized Screening Trial of Innovative Glioblastoma Therapy

Recruiting
2
460
US
Temozolomide, Temodar, Neratinib, QBS10072S
Patrick Wen, MD, Eli Lilly and Company, Celgene, Puma Biotechnology, Inc., Accelerate Brain Cancer Cure, Quadriga Biosciences, Inc.
Glioblastoma
02/27
04/27
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT00268385: Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Active, not recruiting
1
83
US
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
10/18
04/25
NCT02852655: A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Active, not recruiting
1
60
US
MK-3475, Pembrolizumab
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Brain Cancer
06/22
01/26
GMCI, NCT03576612: , Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas

Completed
1
41
US
AdV-tk, Aglatimagene Besadenovec, Valacyclovir, 124832-26-4, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine, Zelitrex, Radiation, Irradiate, irradiation, radiotherapy, RT, Temozolomide, TMZ, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Laboratory Biomarker Analysis
Candel Therapeutics, Inc., National Cancer Institute (NCI), Bristol-Myers Squibb
Glioma, Malignant
06/23
06/23
NCT04606316: Surgical Nivolumab And Ipilimumab For Recurrent GBM

Active, not recruiting
1
63
US
Nivolumab-Placebo, Nivolumab, Opdivo, Ipilimumab-Placebo, Ipilimumab, Yervoy, Surgery, Resection
Patrick Wen, MD, Bristol-Myers Squibb
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
06/25
12/25
NCT03423628: A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Jan 2024 - Dec 2024: Data from trial in combination with radiation therapy for brain metastases
Recruiting
1
180
Europe, Japan, US
Radiation Therapy, Radiotherapy, Radiation treatment, RT, AZD1390, ATM inhibitor
AstraZeneca
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
09/26
09/26
NCT04656535: AB154 Combined With AB122 for Recurrent Glioblastoma

Active, not recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
06/25
12/25
Neelapu, Sattva S
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Active, not recruiting
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
GLEAN-1, NCT04735471: A Phase 1 Study of ADI-001 in B Cell Malignancies

Active, not recruiting
1
78
US
ADI-001, Fludarabine, Cyclophosphamide
Adicet Therapeutics
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
07/25
12/27
NCT05773040: A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Recruiting
1
33
US
JV-213, Leukapheresis
M.D. Anderson Cancer Center
Lymphomas, B-cell Lymphomas
12/25
12/27
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Active, not recruiting
1
16
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
11/25
11/38
Tu, Shi-Ming
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
A031701, NCT03609216: Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Recruiting
2
271
US
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
02/27
02/29
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
NCT06044025: A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

Recruiting
1
30
US
Metformin, Turmeric
University of Arkansas
Castration Sensitive Prostate Cancer
10/26
10/27
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
 

Download Options